EA201200653A1 - Гетариламинохинолины - Google Patents

Гетариламинохинолины

Info

Publication number
EA201200653A1
EA201200653A1 EA201200653A EA201200653A EA201200653A1 EA 201200653 A1 EA201200653 A1 EA 201200653A1 EA 201200653 A EA201200653 A EA 201200653A EA 201200653 A EA201200653 A EA 201200653A EA 201200653 A1 EA201200653 A1 EA 201200653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hetarylaminoquinolines
hetarylaminoquinoline
het
atp
derivatives
Prior art date
Application number
EA201200653A
Other languages
English (en)
Inventor
Альфред Йончик
Кристиане Амендт
Франк Ценке
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201200653A1 publication Critical patent/EA201200653A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Новые гетариламинохинолиновые производные формулы (I)где X, Z, Het, R1, R2, R3 и R4 имеют значения в соответствии с п.1, являются ингибиторами АТФ-связывающих белков и могут использоваться, в частности, для лечения опухолей.
EA201200653A 2009-11-07 2010-10-12 Гетариламинохинолины EA201200653A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09013988 2009-11-07
PCT/EP2010/006239 WO2011054433A1 (en) 2009-11-07 2010-10-12 Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201200653A1 true EA201200653A1 (ru) 2013-01-30

Family

ID=43303813

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200653A EA201200653A1 (ru) 2009-11-07 2010-10-12 Гетариламинохинолины

Country Status (12)

Country Link
US (1) US8987301B2 (ru)
EP (1) EP2496234A1 (ru)
JP (1) JP5827627B2 (ru)
KR (1) KR20130025860A (ru)
CN (1) CN102596200A (ru)
AU (1) AU2010314518B2 (ru)
CA (1) CA2780111A1 (ru)
EA (1) EA201200653A1 (ru)
IL (1) IL219522A0 (ru)
MX (1) MX2012005250A (ru)
WO (1) WO2011054433A1 (ru)
ZA (1) ZA201204138B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110133048A (ko) 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
SI3089971T1 (sl) * 2014-01-01 2020-11-30 Medivation Technologies Llc Spojine in postopki za uporabo
CA2987978C (en) 2014-06-16 2022-08-16 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
WO2016025629A1 (en) * 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
WO2016061280A1 (en) 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
KR101653677B1 (ko) * 2015-04-29 2016-09-05 원광대학교산학협력단 클로로퀸 기반 α,β-불포화아미드 유도체 화합물을 유효성분으로 함유하는 말라리아 감염 질환의 예방 또는 치료용 조성물
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
CN110452168B (zh) * 2018-05-07 2022-03-15 中国医学科学院药物研究所 N-苯基-n-喹啉羧酸类化合物及其制法和药物用途
AU2019362242A1 (en) * 2018-10-18 2021-05-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Compound as TGF-β R1 inhibitor and application thereof
CN110452951B (zh) * 2019-08-16 2021-04-13 珠海丽凡达生物技术有限公司 监测mRNA Poly(A)尾长度的方法及应用
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
CN111303135A (zh) * 2020-04-01 2020-06-19 中科利健制药(广州)有限公司 4-（4-吡唑氧基）喹啉类化合物、其制备方法、药物组合物与应用
CN111269215B (zh) * 2020-04-01 2021-10-26 中科利健制药(广州)有限公司 含氮杂环有机化合物及其制备方法和应用
CN114149410A (zh) * 2020-09-07 2022-03-08 四川科伦博泰生物医药股份有限公司 吡啶并环类化合物及其制备方法和用途
TWI793877B (zh) 2020-11-26 2023-02-21 南韓商Ｌｇ化學股份有限公司 作為甘油二酯激酶抑制劑的雜環化合物及其用途
KR102652004B1 (ko) * 2020-12-10 2024-03-27 엘티소재주식회사 헤테로 고리 화합물, 이를 포함하는 유기 발광 소자, 이의 제조방법 및 유기물층용 조성물
EP4274546A1 (en) * 2021-01-06 2023-11-15 The Penn State Research Foundation Methods and materials for treating hair loss
CA3227603A1 (en) * 2021-08-05 2023-02-09 Jonathan E. Wilson Pparg inverse agonists and uses thereof
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
KR20230164601A (ko) * 2022-05-25 2023-12-04 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
WO2023229380A1 (ko) * 2022-05-25 2023-11-30 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6103M (ru) 1967-02-22 1968-06-10
FR2485014A1 (fr) * 1980-06-20 1981-12-24 Pharmindustrie Nouveaux derives de (quinolyl-2, -3 ou -4)-1 (piperidyl ou pyrrolidinyl-2 ou -3)-2 ou -3 ethanone ou propanone, procedes pour leur preparation, et leur utilisation comme medicaments
NZ209710A (en) * 1983-09-29 1988-02-12 Akzo Nv Quinazoline and isoquinoline derivatives and pharmaceutical and veterinary compositions containing such
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2114727C (en) 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
WO2000076982A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
WO2001012608A1 (fr) 1999-08-18 2001-02-22 Nippon Soda Co., Ltd. Composes de quinoline et procede de preparation desdits composes
SE0004054D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SE0102858D0 (sv) 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
US7713983B2 (en) * 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ATE398125T1 (de) * 2003-03-12 2008-07-15 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
ES2389258T3 (es) * 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
JP4722851B2 (ja) 2003-09-23 2011-07-13 メルク・シャープ・エンド・ドーム・コーポレイション キノリンカリウムチャネル阻害剤
WO2006058201A2 (en) * 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
TWI439452B (zh) * 2005-05-13 2014-06-01 Otsuka Pharma Co Ltd 吡咯烷化合物（二）
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CA2765823A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Tricyclic heterocyclic compounds as mediators of p13k activity

Also Published As

Publication number Publication date
JP2013510103A (ja) 2013-03-21
WO2011054433A1 (en) 2011-05-12
KR20130025860A (ko) 2013-03-12
MX2012005250A (es) 2012-06-14
CA2780111A1 (en) 2011-05-12
IL219522A0 (en) 2012-06-28
AU2010314518B2 (en) 2016-04-21
US8987301B2 (en) 2015-03-24
US20120225875A1 (en) 2012-09-06
CN102596200A (zh) 2012-07-18
JP5827627B2 (ja) 2015-12-02
EP2496234A1 (en) 2012-09-12
ZA201204138B (en) 2013-02-27
AU2010314518A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
EA201200653A1 (ru) Гетариламинохинолины
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201201170A1 (ru) Гетариламинонафтиридины
EA201000093A1 (ru) Производные пиридазинона
EA201100966A1 (ru) Производные пиридазинона
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
EA201000004A1 (ru) Производные 6-(пирролопиридинил)пиримидин-2-иламина и их применение для лечения злокачественного новообразования и спида
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
EA200901601A1 (ru) Производные пиридазинона
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
EA201001648A1 (ru) Производные пиридазинона
EA201101085A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
EA201000549A1 (ru) Производные пиперидина и пиперазина
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201300282A1 (ru) Производные триазолопиразина
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
EA200801430A1 (ru) Производные триазола